氨磺必利治疗精神分裂症的有效性和安全性临床观察  

The clinical efficacy of Amisulpride in the treatment of schizophrenia

作　　者：刘萍[1] 高欢[2] 

机构地区：[1]广东省珠海市康宁路79号珠海市人民医院心理科,广东珠海519000 [2]广东省深圳市康宁医院

出　　处：《中国民康医学》2013年第15期56-57,共2页Medical Journal of Chinese People’s Health

摘　　要：目的:探讨氨磺必利片治疗精神分裂症的有效性和安全性。方法:用氨磺必利片治疗精神分裂症共57例,疗程8周,用简明精神病评定量表(BPRS)和副反应量表(TESS)评定疗效及不良反应。结果:完成8周治疗的57例精神分裂症患者的疗效为:痊愈30例(52.6%)显著进步17例(29.8%)、进步7例(12.3%)、无效3例(5.3%),总有效率为94.7%;不良反应轻微。结论:氨磺必利片治疗精神分裂症临床疗效较好,尤对阴性症状的改善更为显著,不良反应较轻,安全性较高,依从性较佳。Objective： To determine the clinical efficacy and safety of amisulpride in the treatment of schizophrenia.Methods： 57 patients with first episode schizophrenia were treated with olanzapine for 8 weeks,and assessed with BPRS and TESS for the efficacy and safety.Results： 57 cases who completed the 8 weeks treatment,30 cases（52.6%） were cured,17 cases（29.8%） were significantly improved,7cases（12.3%） improved and 3 cases（5.3%） had no response.Total effective rate was 94.7%,with effect and mild obvious side effect.Conclusions： The study suggests that amisulpride is a safe,effective agent in the treatment of schizophrenia.

关 键 词：氨磺必利片 精神分裂症 有效性 安全性 

分 类 号：R749.3[医药卫生—神经病学与精神病学]